Stocktoria
Silo Pharma, Inc. SILO
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2012-01-05
Silo Pharma, Inc. financials (annual)
Bars are annual figures from 2013 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72,102 | $72,102 | $72,102 | $72,102 | — | $40,923 | $40,569 | — | — | — |
| Gross profit | $27,807 | $66,264 | $66,264 | $66,264 | $66,260 | -$135,203 | $13,182 | — | — | — |
| R&D expense | $2.2M | $2.4M | $845,092 | $1.3M | $693,910 | $26,250 | — | — | — | — |
| SG&A expense | — | — | $390,071 | $227,259 | $162,953 | $50,192 | — | — | — | — |
| Operating income | -$4.3M | -$4.7M | -$3.9M | -$3.6M | -$2.7M | -$2.2M | -$930,403 | -$594,242 | -$490,871 | — |
| Interest expense | — | — | $4,869 | $2,199 | $3,036 | $80 | $0 | — | — | — |
| Income tax | — | — | — | — | $24,876 | — | — | — | — | — |
| Net income | -$4.2M | -$4.4M | -$3.7M | -$3.9M | $3.9M | -$3.0M | -$1.0M | -$969,463 | $356,536 | — |
| EPS (diluted) | $-0.50 | $-1.19 | $-1.20 | — | $0.04 | $-0.05 | — | $-0.02 | $0.01 | — |
| Operating cash flow | -$4.7M | -$3.8M | -$3.2M | -$3.5M | -$2.3M | -$1.2M | -$794,324 | $272,637 | -$284,618 | -$181,609 |
| Cash & equivalents | $4.7M | $3.9M | $3.5M | $11.4M | $9.8M | $1.1M | $111,752 | $336,679 | $294,591 | $2.0M |
| Inventory | — | — | — | — | — | $33,484 | $156,366 | $26,973 | — | — |
| Total assets | $7.6M | $7.4M | $7.7M | $11.6M | $10.5M | $1.4M | $493,845 | $855,417 | $1.6M | $2.2M |
| Total liabilities | $1.3M | $2.4M | $1.6M | $1.3M | $1.4M | $145,969 | $116,737 | — | — | $18,717 |
| Shareholders' equity | $6.3M | $5.0M | $6.2M | $10.3M | $9.1M | $1.3M | -$22,892 | $407,442 | $1.2M | $1.8M |
Growth · year-over-year · Revenue CAGR 12.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +0.0% | +0.0% | +0.0% | — | — | +0.9% | — | — | — | — |
| Net income growth | — | — | — | -200.1% | — | — | — | -371.9% | — | — |
| EPS growth | — | — | — | — | — | — | — | -300.0% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.